CSPC Innovation Pharmaceutical (SHE:300765) subsidiary CSPC Jushi Biopharmaceutical has launched a Phase III clinical trial for its cancer therapy, SYS6010, according to a Shenzhen Stock Exchange filing on Wednesday.
The trial targets patients with resected stage II-IIIB driver gene-negative non-small cell lung cancer who did not achieve a major pathological response after previous treatment.
SYS6010 is a novel antibody-drug conjugate approved by China's National Medical Products Administration in June.